Matthew Perry Net Worth

The estimated Net Worth of Matthew D Perry is at least $5.57 Million dollars as of 11 December 2020. Mr. Perry owns over 200,000 units of XOMA Royalty stock worth over $5,424,000 and over the last 9 years he sold XOMA stock worth over $0. In addition, he makes $145,992 as Independent Director at XOMA Royalty.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Perry XOMA stock SEC Form 4 insiders trading

Matthew has made over 2 trades of the XOMA Royalty stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of XOMA stock worth $5,000,000 on 11 December 2020.

The largest trade he's ever made was buying 200,000 units of XOMA Royalty stock on 11 December 2020 worth over $5,000,000. On average, Matthew trades about 9,924 units every 68 days since 2016. As of 11 December 2020 he still owns at least 200,000 units of XOMA Royalty stock.

You can see the complete history of Mr. Perry stock trades at the bottom of the page.

Matthew Perry biography

Matthew D. Perry serves as Independent Director of the Company. Mr. Perry has been a director since February 2017. Mr. Perry is the President of BVF Partners L.P. (“BVF Partners”) and portfolio manager for the underlying funds managed by the firm. BVF Partners is a private investment partnership that has focused on small-cap, value oriented investment opportunities for more than 20 years. Mr. Perry joined BVF Partners in December 1996 and has been a successful lead investor in dozens of transactions and has positively influenced corporate direction for numerous biotechnology companies during the course of his career. In January 2016, Mr. Perry was named to CTI BioPharma Corp.’s Board of Directors and is a member of its Compensation Committee. Mr. Perry is also a co-founder and director of Nordic Biotech Advisors ApS, a venture capital firm based in Copenhagen, Denmark. He holds a B.S. degree from the Biology Department at the College of William and Mary. Mr. Perry brings extensive management consulting experience and experience investing in biotechnology companies to the Board.

What is the salary of Matthew Perry?

As the Independent Director of XOMA Royalty, the total compensation of Matthew Perry at XOMA Royalty is $145,992. There are 8 executives at XOMA Royalty getting paid more, with James Neal having the highest compensation of $1,479,560.

How old is Matthew Perry?

Matthew Perry is 47, he's been the Independent Director of XOMA Royalty since 2017. There are 6 older and 1 younger executives at XOMA Royalty. The oldest executive at XOMA Royalty Corp. is W. Denman Van Ness, 77, who is the Independent Chairman of the Board.

What's Matthew Perry's mailing address?

Matthew's mailing address filed with the SEC is C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE, CA, 94608.

Insiders trading at XOMA Royalty

Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.

What does XOMA Royalty do?

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.

Complete history of Mr. Perry stock trades at CTI BioPharma Corp and XOMA Royalty

XOMA Royalty executives and stock owners

XOMA Royalty executives and other stock owners filed with the SEC include:

• James Neal,
  Chief Executive Officer, Director
• Thomas Burns,
  Chief Financial Officer, Senior Vice President - Finance
• James R. Neal,
  CEO & Chairman
• Thomas M. Burns,
  Sr. VP of Fin. & CFO
• Barbara Kosacz,
  Independent Director
• W. Denman Van Ness,
  Independent Chairman of the Board
• Jack Wyszomierski,
  Independent Director
• Joseph Limber,
  Independent Director
• Matthew Perry,
  Independent Director
• Natasha Hernday,
  Director
• Deepshikha Datta,
  Chief Business Officer
• Timothy P Walbert,
  Director
• Peter Barton Hutt,
  Director
• Paul D Rubin,
  VP Clinical Dev. & CMO
• Steven B Engle,
  CEO and President
• Charles J Jr Fisher,
  Director
• Patrick J Zenner,
  Director
• John Varian,
  Director
• Owen Hughes,
  Chief Executive Officer
• Partners L P/Ilbiotechnolog...,
  
• Fred Kurland,
  VP Finance
• Thomas Klein,
  Chief Commercial Officer
• William K Jr Bowes,
  Director
• Bros. Advisors Lp667, L.P.B...,
  
• Bros. Advisors Lpbaker Feli...,
  
• Bros Advisors Llcbaker Feli...,
  
• Patrick J Md Phd Scannon,
  CSMO
• Kelvin Neu,
  Director
• Julianbaker Bros Advisors L...,
  
• J David Ii Boyle,
  VP, Finance, and CFO
• Arthur Md Kornberg,
  Director
• John L Castello,
  Chairman, CEO & President
• James G Andress,
  Director
• Peter B Davis,
  VP, Finance & CFO
• Clarence L Dellio,
  Sr VP, Operations and COO
• Steven C Mendell,
  Director
• Christopher J Margolin,
  VP, General Counsel & Sec'y
• Partners L P/Ilbiotechnolog...,
  
• Heather L Franklin,
  
• Bradley Sitko,
  Chief Investment Officer